Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001792" target="_blank" >RIV/65269705:_____/12:#0001792 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/13:00067535 RIV/65269705:_____/13:#0002041
Výsledek na webu
<a href="http://dx.doi.org/10.1002/hon.2018" target="_blank" >http://dx.doi.org/10.1002/hon.2018</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1002/hon.2018" target="_blank" >10.1002/hon.2018</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients
Popis výsledku v původním jazyce
We investigated the prognostic value of amp(1q21) alone and in combination with other abnormalities in newly diagnosed myeloma patients. The study group consisted of 104 patients treated with various induction regimens, mostly thalidomide based (87 patients). Amp(1q21) was detected in 49 (47.1%) of patients; in 26 (25.0%) cases, it was combined with del(13q14), in 7 (6.7%) with del(17p13) and in 15 (14.4%) with t(4;14)( p16;q32). The response rate was significantly better in amp(1q21)-negative than in amp(1q21)-positive patients (74.5% vs 55.1%, p = 0.025; complete response 18.2% vs 4.1%, p = 0.024). The median progression-free survival (PFS) was 33.9months in patients without amp(1q21) and 10.3months with this aberration ( p = 0.002). The presence ofadditional abnormalities resulted in significantly shortened PFS when compared with patients with isolated amp (1q21): coexisting del(13q14) resulted in 7.8 vs 29.0months of PFS ( p = 0.024) and del (17p13) resulted in 4.0 vs 24.9months o
Název v anglickém jazyce
Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients
Popis výsledku anglicky
We investigated the prognostic value of amp(1q21) alone and in combination with other abnormalities in newly diagnosed myeloma patients. The study group consisted of 104 patients treated with various induction regimens, mostly thalidomide based (87 patients). Amp(1q21) was detected in 49 (47.1%) of patients; in 26 (25.0%) cases, it was combined with del(13q14), in 7 (6.7%) with del(17p13) and in 15 (14.4%) with t(4;14)( p16;q32). The response rate was significantly better in amp(1q21)-negative than in amp(1q21)-positive patients (74.5% vs 55.1%, p = 0.025; complete response 18.2% vs 4.1%, p = 0.024). The median progression-free survival (PFS) was 33.9months in patients without amp(1q21) and 10.3months with this aberration ( p = 0.002). The presence ofadditional abnormalities resulted in significantly shortened PFS when compared with patients with isolated amp (1q21): coexisting del(13q14) resulted in 7.8 vs 29.0months of PFS ( p = 0.024) and del (17p13) resulted in 4.0 vs 24.9months o
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Hematological Oncology
ISSN
0278-0232
e-ISSN
—
Svazek periodika
30
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
9
Strana od-do
1-8
Kód UT WoS článku
000315968100008
EID výsledku v databázi Scopus
—